Classification of anticancer drugs--a new system based on therapeutic targets - PubMed (original) (raw)
Review
Classification of anticancer drugs--a new system based on therapeutic targets
Enrique Espinosa et al. Cancer Treat Rev. 2003 Dec.
Abstract
The arrival of a great number of new antineoplastic agents has made it necessary to reclassify all of them. Anticancer drugs may act at different levels: cancer cells, endothelium, extracellular matrix, the immune system or host cells. The tumour cell can be targeted at the DNA, RNA or protein level. Most classical chemotherapeutic agents interact with tumour DNA, whereas monoclonal antibodies and small molecules are directed against proteins. The endothelium and extracellular matrix may be affected also by specific antibodies and small molecules.
Similar articles
- A new classification system of anticancer drugs - based on cell biological mechanisms.
Wu XZ. Wu XZ. Med Hypotheses. 2006;66(5):883-7. doi: 10.1016/j.mehy.2005.11.036. Epub 2006 Jan 18. Med Hypotheses. 2006. PMID: 16414204 - 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.
Perchellet EM, Magill MJ, Huang X, Dalke DM, Hua DH, Perchellet JP. Perchellet EM, et al. Anticancer Drugs. 2000 Jun;11(5):339-52. doi: 10.1097/00001813-200006000-00004. Anticancer Drugs. 2000. PMID: 10912950 - Developing targeted therapies for lung cancer.
Gandara DR. Gandara DR. Clin Adv Hematol Oncol. 2003 Nov;1(11):648-9, 690. Clin Adv Hematol Oncol. 2003. PMID: 16258461 No abstract available. - Emerging treatments in acute myeloid leukaemia.
Kell J. Kell J. Expert Opin Emerg Drugs. 2004 May;9(1):55-71. doi: 10.1517/eoed.9.1.55.32955. Expert Opin Emerg Drugs. 2004. PMID: 15155136 Review. - Discovery of new anticancer drugs by computer-aided drug design.
Neidle S. Neidle S. Ann Oncol. 1994;5 Suppl 4:51-4. doi: 10.1093/annonc/5.suppl_4.s51. Ann Oncol. 1994. PMID: 8060897 Review.
Cited by
- Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.
Tsvetkova D, Ivanova S. Tsvetkova D, et al. Molecules. 2022 Apr 11;27(8):2466. doi: 10.3390/molecules27082466. Molecules. 2022. PMID: 35458666 Free PMC article. Review. - Cell surface binding, uptaking and anticancer activity of L-K6, a lysine/leucine-rich peptide, on human breast cancer MCF-7 cells.
Wang C, Dong S, Zhang L, Zhao Y, Huang L, Gong X, Wang H, Shang D. Wang C, et al. Sci Rep. 2017 Aug 15;7(1):8293. doi: 10.1038/s41598-017-08963-2. Sci Rep. 2017. PMID: 28811617 Free PMC article. - Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.
Han X, Zhou Y, Liu W. Han X, et al. NPJ Precis Oncol. 2017 Sep 12;1(1):31. doi: 10.1038/s41698-017-0034-x. eCollection 2017. NPJ Precis Oncol. 2017. PMID: 29872712 Free PMC article. Review. - Highlights in Resistance Mechanism Pathways for Combination Therapy.
Delou JMA, Souza ASO, Souza LCM, Borges HL. Delou JMA, et al. Cells. 2019 Aug 30;8(9):1013. doi: 10.3390/cells8091013. Cells. 2019. PMID: 31480389 Free PMC article. Review. - The dual interaction of antimicrobial peptides on bacteria and cancer cells; mechanism of action and therapeutic strategies of nanostructures.
Parchebafi A, Tamanaee F, Ehteram H, Ahmad E, Nikzad H, Haddad Kashani H. Parchebafi A, et al. Microb Cell Fact. 2022 Jun 18;21(1):118. doi: 10.1186/s12934-022-01848-8. Microb Cell Fact. 2022. PMID: 35717207 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources